Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BIIB023 - low dose IV Dose, BIIB023- low dose Dose, Human glycosylated IgG1 monoclonal antibody
BIIB023 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | BIIB023 |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BIIB023 | DRUG | Single IV doses of BIIB023 in dose-escalating cohorts |
| Placebo (sterile normal saline) | OTHER | Single IV dose of Placebo |
Inclusion Criteria: * Diagnosis of adult onset RA (functional class I-III) for at least 6 months * Must have been treated with and be tolerating Methotrexate (5-25 mg/week) for 3 months, at a stable dose for at least 4 weeks * Must have at least 4 swollen and tender joints due to rheumatoid arthrit...
Top 20 of 31 competitors
BIIB023 is an investigational small molecule being studied for the treatment of rheumatoid arthritis, an inflammatory autoimmune condition affecting the joints. It was evaluated in a Phase 1 clinical trial in adults with rheumatoid arthritis. BIIB023 is not approved for any indication and remains in clinical development.
BIIB023 is being developed by Biogen Inc., which trades on the Nasdaq under the ticker BIIB. Biogen sponsored the Phase 1 clinical trial of BIIB023 in rheumatoid arthritis. The company is the sole developer identified for this asset.
BIIB023 is in Phase 1 clinical development. It has completed one Phase 1 trial in rheumatoid arthritis, and no active trials are currently listed. BIIB023 is investigational and has not been approved by the FDA for any use.
BIIB023 has been studied in one completed Phase 1 trial, NCT00771329, titled "BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis." The trial enrolled 53 participants across the United States and Russia. It was randomized, double-blind, and placebo-controlled, and included adults 18 years and older.
Yes, BIIB023 is also referred to as BIIB023 low dose IV Dose and BIIB023 low dose Dose. These names describe the low-dose intravenous formulation evaluated in its Phase 1 rheumatoid arthritis trial. All refer to the same investigational compound developed by Biogen.